C section News and Research

RSS

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Novo Nordisk receives Good Design Award from Japan Industrial Design Promotion Organization

Novo Nordisk has been awarded a Good Design Award(TM) for NovoTwist(TM), the new needle designed for use with the insulin delivery device FlexPen(R). The needle, which has a simple 'just twist' attachment and detachment, makes injection easier for people with diabetes.

From Novo Nordisk 26 Oct 2009

Orthovita to present comparative study data of its Cortoss product to polymethylmethacrylate

Orthovita, Inc., an orthobiologics and biosurgery company, is pleased to announce that Dr. Pierce D. Nunley, Director of the Spine Institute of Louisiana, will present his abstract, “A Comparison of Clinical Outcomes and Adjacent Level Fractures in Patients Receiving Vertebroplasty for Osteoporotic Compression Fractures Using CortossTM or PMMA: A Prospective, Randomized Trial,” at the 2009 Annual Meeting of the Congress of Neurological Surgeons (CNS).

24 Oct 2009

CMPro software for CMS reporting requirements

rL Solutions, the leading provider of healthcare quality and safety software, announced today that its claims management software, Claims MonitorPro(R) (CMPro) can assist healthcare organizations in meeting the new CMS Section 111 reporting requirements.

24 Oct 2009

Justice Department intervenes to protect civil rights of the mentally ill in New York

The Justice Department today filed a motion to intervene in Disability Advocates Inc. v. David A. Paterson, et al. in federal court in the Eastern District of New York.

24 Oct 2009

Updated data on XL184 study in patients with glioblastoma multiforme presented

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

24 Oct 2009

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, today announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma.

24 Oct 2009

Seattle Genetics reports its third-quarter financial results

Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.

24 Oct 2009

Illegal residents' view on healthcare status

The dissertation focuses on how individual non-citizens residing illegally in the country perceive their health status, what wishes they have regarding healthcare, and whether these wishes are fulfilled. The individual perspective is used instead of the more common concepts of health and healthcare needs, which are based more on the care-giver perspective.

22 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

ImmunoGen to host a conference call to discuss its financial results

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, October 29, 2009 to discuss the Company’s financial results for the three-month period ended September 30, 2009 – the first quarter of ImmunoGen’s 2010 fiscal year.

22 Oct 2009

Drug expert to discuss recent policy shift in medical marijuana at 2009 Symposium

The National Association of Boards of Pharmacy(R) (NABP(R)) welcomes Office of National Drug Control Policy drug policy expert Kevin Sebat to speak at its 2009 Symposium. On December 3, 2009, Sebat will discuss the current federal laws regarding marijuana as well as the recent policy shift regarding prosecution of medical marijuana cases in states that have legalized the practice.

22 Oct 2009

18 Los Angeles residents charged in five indictments for allegedly participating in Medicare fraud schemes

Eighteen defendants, most of them residing in the Los Angeles area, have been charged in five indictments for allegedly participating in Medicare fraud schemes that resulted in approximately $25 million in fraudulent bills to the Medicare program, announced Assistant Attorney General of the Criminal Division Lanny A. Breuer, Acting U.S. Attorney for the Central District of California George S. Cardona and Daniel R. Levinson, Inspector General of the Department of Health & Human Services (HHS).

22 Oct 2009

COOKIE DIET web site reaches milestone; registers its 100,000th member

At 6:14pm yesterday, Debora Gore of Bristow, Virginia, received a phone call from renowned physician, author, and weight-loss expert Dr. Sanford Siegal who was calling to congratulate her on becoming the 100,000th registered member of CookieDiet.com, the official Dr. Siegal's COOKIE DIET® web site.

22 Oct 2009

Experts discuss methods to prevent catheter-associated urinary tract infections

It's a statistic that almost every healthcare facility knows: 40 percent of all healthcare-acquired infections are urinary tract infections (UTI). Since catheters -- the most common source of these infections -- are used on over four million hospital patients a year, the chances of a patient getting a UTI are pretty high. In fact, the daily risk for patients acquiring a urinary infection is as high as seven percent when indwelling urethral catheters remain in their original position.

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 8th Annual BIO Investor Forum at 4:30 p.m. PDT (7:30 p.m. EDT) on October 28, 2009, at the Palace Hotel in San Francisco, California.

21 Oct 2009

MUSC launches Social Media Newsroom for real-time information on medical news and research

As the editorial landscape continues to evolve with the emergence of social media, many people struggle to find trusted resources that offer accurate, real time information related to healthcare news and research.

21 Oct 2009

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

People living with diabetes to increase up to 435 million by 2030

The latest International Diabetes Federation (IDF) data reveals that over 285 million people worldwide now live with diabetes and this number will explode to 435 million by 2030. This staggering figure does not capture the toll the disease takes on the individual. Unlike other diseases, people with diabetes are responsible for 95% of their own care and many are doing so without the proper skills and knowledge to do so.

21 Oct 2009

C section News and Research

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Novo Nordisk receives Good Design Award from Japan Industrial Design Promotion Organization

Orthovita to present comparative study data of its Cortoss product to polymethylmethacrylate

CMPro software for CMS reporting requirements

Justice Department intervenes to protect civil rights of the mentally ill in New York

Updated data on XL184 study in patients with glioblastoma multiforme presented

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

Seattle Genetics reports its third-quarter financial results

Illegal residents' view on healthcare status

Schering-Plough announces 2009 third quarter financial results

ImmunoGen to host a conference call to discuss its financial results

Drug expert to discuss recent policy shift in medical marijuana at 2009 Symposium

18 Los Angeles residents charged in five indictments for allegedly participating in Medicare fraud schemes

COOKIE DIET web site reaches milestone; registers its 100,000th member

Experts discuss methods to prevent catheter-associated urinary tract infections

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

MUSC launches Social Media Newsroom for real-time information on medical news and research

Oxygen Biotherapeutics announces its expanded product development plan

People living with diabetes to increase up to 435 million by 2030

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News